S&P 500   3,960.00 (+0.66%)
DOW   33,810.65 (+0.63%)
QQQ   283.74 (+1.14%)
AAPL   142.99 (+1.45%)
MSFT   246.80 (+0.99%)
META   115.67 (+1.53%)
GOOGL   93.92 (-1.07%)
AMZN   90.03 (+1.77%)
TSLA   172.47 (-0.90%)
NVDA   167.15 (+3.69%)
NIO   13.34 (+6.04%)
BABA   92.98 (+5.26%)
AMD   70.49 (+0.50%)
T   19.28 (-0.10%)
MU   55.49 (+3.10%)
CGC   3.18 (-1.85%)
F   13.20 (+0.76%)
GE   84.29 (-0.84%)
DIS   92.69 (+0.59%)
AMC   6.30 (+4.13%)
PYPL   75.22 (+1.07%)
PFE   50.81 (+1.13%)
NFLX   309.14 (+0.23%)
S&P 500   3,960.00 (+0.66%)
DOW   33,810.65 (+0.63%)
QQQ   283.74 (+1.14%)
AAPL   142.99 (+1.45%)
MSFT   246.80 (+0.99%)
META   115.67 (+1.53%)
GOOGL   93.92 (-1.07%)
AMZN   90.03 (+1.77%)
TSLA   172.47 (-0.90%)
NVDA   167.15 (+3.69%)
NIO   13.34 (+6.04%)
BABA   92.98 (+5.26%)
AMD   70.49 (+0.50%)
T   19.28 (-0.10%)
MU   55.49 (+3.10%)
CGC   3.18 (-1.85%)
F   13.20 (+0.76%)
GE   84.29 (-0.84%)
DIS   92.69 (+0.59%)
AMC   6.30 (+4.13%)
PYPL   75.22 (+1.07%)
PFE   50.81 (+1.13%)
NFLX   309.14 (+0.23%)
S&P 500   3,960.00 (+0.66%)
DOW   33,810.65 (+0.63%)
QQQ   283.74 (+1.14%)
AAPL   142.99 (+1.45%)
MSFT   246.80 (+0.99%)
META   115.67 (+1.53%)
GOOGL   93.92 (-1.07%)
AMZN   90.03 (+1.77%)
TSLA   172.47 (-0.90%)
NVDA   167.15 (+3.69%)
NIO   13.34 (+6.04%)
BABA   92.98 (+5.26%)
AMD   70.49 (+0.50%)
T   19.28 (-0.10%)
MU   55.49 (+3.10%)
CGC   3.18 (-1.85%)
F   13.20 (+0.76%)
GE   84.29 (-0.84%)
DIS   92.69 (+0.59%)
AMC   6.30 (+4.13%)
PYPL   75.22 (+1.07%)
PFE   50.81 (+1.13%)
NFLX   309.14 (+0.23%)
S&P 500   3,960.00 (+0.66%)
DOW   33,810.65 (+0.63%)
QQQ   283.74 (+1.14%)
AAPL   142.99 (+1.45%)
MSFT   246.80 (+0.99%)
META   115.67 (+1.53%)
GOOGL   93.92 (-1.07%)
AMZN   90.03 (+1.77%)
TSLA   172.47 (-0.90%)
NVDA   167.15 (+3.69%)
NIO   13.34 (+6.04%)
BABA   92.98 (+5.26%)
AMD   70.49 (+0.50%)
T   19.28 (-0.10%)
MU   55.49 (+3.10%)
CGC   3.18 (-1.85%)
F   13.20 (+0.76%)
GE   84.29 (-0.84%)
DIS   92.69 (+0.59%)
AMC   6.30 (+4.13%)
PYPL   75.22 (+1.07%)
PFE   50.81 (+1.13%)
NFLX   309.14 (+0.23%)
NASDAQ:MBRX

Moleculin Biotech - MBRX Price Target & Analyst Ratings

$1.48
-0.01 (-0.67%)
(As of 12/8/2022 10:41 AM ET)
Add
Compare
Today's Range
$1.46
$1.48
50-Day Range
$0.87
$1.49
52-Week Range
$0.82
$2.33
Volume
9 shs
Average Volume
87,390 shs
Market Capitalization
$42.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50

Moleculin Biotech Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 1 Analyst Ratings

Consensus Analyst Price Target

$10.50
609.46% Upside
High Prediction$16.00
Average Prediction$10.50
Low Prediction$5.00
TypeCurrent
12/8/21 to 12/8/22
1 Month Ago
11/8/21 to 11/8/22
3 Months Ago
9/9/21 to 9/9/22
1 Year Ago
12/8/20 to 12/8/21
Consensus Rating
Buy
Buy
Buy
N/A
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
N/A
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
N/A
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
N/A
Consensus Price Target$10.50$15.00$15.00N/A
Predicted Upside609.46% Upside760.42% Upside760.42% UpsideN/A
Get Moleculin Biotech Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter.


MBRX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MBRX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Moleculin Biotech Stock vs. The Competition

TypeMoleculin BiotechMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.66
2.48
Consensus RatingBuyBuyHold
Predicted Upside619.18% Upside598.05% Upside14.73% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
222
62.54%
Underperform Votes
133
37.46%
Avg. Outperform Votes
163
66.26%
Avg. Underperform Votes
83
33.74%
Avg. Outperform Votes
853
68.13%
Avg. Underperform Votes
399
31.87%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/11/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$14.00 ➝ $5.00+454.93%
8/16/2022Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$29.00 ➝ $16.00+803.95%
6/9/2020Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jason McCarthy
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$18.00+156.41%
(Data available from 12/8/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












MBRX Price Target - Frequently Asked Questions

What is Moleculin Biotech's consensus rating and price target?

According to the issued ratings of 1 analysts in the last year, the consensus rating for Moleculin Biotech stock is Buy based on the current 1 buy rating for MBRX. The average twelve-month price prediction for Moleculin Biotech is $10.50 with a high price target of $16.00 and a low price target of $5.00. Learn more on MBRX's analyst rating history.

Do Wall Street analysts like Moleculin Biotech more than its competitors?

Analysts like Moleculin Biotech more than other Medical companies. The consensus rating score for Moleculin Biotech is 3.00 while the average consensus rating score for medical companies is 2.66. Learn more on how MBRX compares to other companies.

Do MarketBeat users like Moleculin Biotech more than its competitors?

MarketBeat users like Moleculin Biotech less than other Medical companies. 62.54% of MarketBeat users gave Moleculin Biotech an outperform vote while medical companies recieve an average of 66.26% outperform votes by MarketBeat users.

Does Moleculin Biotech's stock price have much upside?

According to analysts, Moleculin Biotech's stock has a predicted upside of 615.75% based on their 12-month price targets.

What analysts cover Moleculin Biotech?

Moleculin Biotech has been rated by Oppenheimer in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:MBRX) was last updated on 12/8/2022 by MarketBeat.com Staff